[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617921":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":23,"locations":28,"responsibleParty":58,"collaborators":10,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":10,"studyType":75,"phases":10,"briefSummary":76,"conditions":77,"keywords":81,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"University of Athens","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Participants with elevated Lipoprotein a",null,"Group A: PArticipants with elevated Lp(a) (Lp(a) ≥50 mg\u002FdL) with normal Total Cholesterol levels (Cholesterol\\\u003C200 mg\u002Fdl). All participants (n≥100) will undergo assessment of arterial stiffness by measing PWV, evaluation of thickness of endothelial glycocalyx bymeasuring PBR, assessment of myocardial deformation by measuring LA strain and LV GLS and quantification of oxidative stress burden by measuring MDa and PCs at baseline, at 6 months and at 12 months.",{"label":13,"type":10,"description":14,"interventionNames":10},"Participants with elevated Total Cholesterol","Group B: PArticipants with normal Lp(a) (Lp(a) \\\u003C50 mg\u002FdL) with elevated Total Cholesterol levels (Cholesterol ≥200 mg\u002Fdl).\n\nAll participants (n≥100) will undergo assessment of arterial stiffness by measing PWV, evaluation of thickness of endothelial glycocalyx bymeasuring PBR, assessment of myocardial deformation by measuring LA strain and LV GLS and quantification of oxidative stress burden by measuring MDa and PCs at baseline, at 6 months and at 12 months.",{"label":16,"type":10,"description":17,"interventionNames":10},"Participants with normal lipids levels","Group C: PArticipants with Lp(a) (Lp(a) \\\u003C50 mg\u002FdL) and TotalCholesterol levels (Cholesterol ≥200 mg\u002Fdl) within reference range.\n\nAll participants (n≥100) will undergo assessment of arterial stiffness by measing PWV, evaluation of thickness of endothelial glycocalyx bymeasuring PBR, assessment of myocardial deformation by measuring LA strain and LV GLS and quantification of oxidative stress burden by measuring MDa and PCs at baseline, at 6 months and at 12 months.",[19],{"name":20,"affiliation":21,"role":22},"Ignatios Ikonomidis","National and Kapodistrian University of Athens","PRINCIPAL_INVESTIGATOR",[24],{"name":20,"role":25,"phone":26,"phoneExt":10,"email":27},"CONTACT","+30 694 4805732","ignoik@gmail.com",[29,48],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"\"Attikon\" University General Hospital","RECRUITING","Athens","Attica","12462","Greece","GR",{"type":38,"coordinates":39},"Point",[40,41],23.72784,37.98376,{"lat":41,"lon":40},[44,47],{"name":45,"role":25,"phone":46,"phoneExt":10,"email":10},"Ignatios Ikonomidis, MD","00302105832187",{"name":45,"role":22,"phone":10,"phoneExt":10,"email":10},{"facility":49,"status":31,"city":32,"state":50,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":51,"geoPoint":53,"contacts":54},"Attikon University Hospital, 2nd Department of Cardiology, National and Kapodistrina University of Athens","Rimini 1",{"type":38,"coordinates":52},[40,41],{"lat":41,"lon":40},[55],{"name":56,"role":25,"phone":57,"phoneExt":10,"email":27},"Ignatios Ikonomidis, MD;PhD","+30644805732",{"type":22,"investigatorFullName":20,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Professor of Cardiology","100617921","the-effect-of-lipoprotein-a-on-arterial-stiffness-endothelial-function-and-myocardial-deformation-100617921",false,"NCT07324902","The Effect of Lipoprotein (a) on Arterial Stiffness, Endothelial Function and Myocardial Deformation","The Effect of Lipoprotein (a) on Arterial Stiffness, Endothelial Function and Left Atrial and Left Ventricular Deformation - An Observational Study.","Lpa_endo","Inclusion Criteria:\n\n* Adults participants 18-75 years old\n* Willing to sign the informed consent and paerticipate in the study\n\nExclusion Criteria:\n\n* History of autoimmune\u002Fautoinflammatory disease,\n* Severe valvular heart disease,\n* severe chronic kidney disease(eGFR\\\u003C60 ml\u002Fmin\u002F1.73 m2),\n* Active Pregnancy\n* Severe hepatic impairment.",true,"ALL","18 Years","75 Years",{"count":73,"type":74},300,"ESTIMATED","OBSERVATIONAL","1. Introduction Lipoprotein(a), or Lp(a), is a type of lipoprotein that is structurally similar to LDL (low-density lipoprotein) but carries an additional protein called apolipoprotein (a).\n2. Purpose of the Study\n\n   The primary purpose of this study is to investigate the effect of Lp(a) levels on arterial stiffness, endothelial function, and left atrial (LA) and left ventricular (LV) deformation over a 12-month follow-up period.\n\n   Secondarily, the study will investigate:\n   * a) The incidence of major adverse cardiovascular events (MACE), including cardiovascular death, acute myocardial infarction, and acute stroke.\n   * b) The correlation between MACE incidence and parameters of arterial stiffness, endothelial function, and LA\u002FLV deformation.\n   * c) The levels of oxidative load markers.\n3. Materials and Methods This observational study will include adults aged 18-75 years (regardless of gender) who visit the outpatient clinics of the 2nd University Cardiology Clinic at \"Attikon\" General Hospital. All participants will sign a consent form. A full medical history, clinical examination, and blood collection will be performed to determine levels of Total Cholesterol, LDL-C, HDL-C, triglycerides, and Lp(a) at each visit..\n\nParticipants will be divided into three groups:\n\n* Group A: Lp(a) ≥50 mg\u002FdL with Total Cholesterol\\\u003C200 mg\u002Fdl\n* Group B : Lp(a) \\\u003C50 mg\u002FdL. with Total Cholesterol\\>200 mg\u002Fdl\n* Group C (Control): Lp(a) \\\u003C50 mg\u002FdL. with Total Cholesterol\\\u003C200 mg\u002Fdl At each group n ≥ 100 participants are anticipated.\n\nMeasurements at baseline, at 6 and at 12 months:\n\n* Arterial Stiffness: Determination of carotid-femoral pulse wave velocity (cf-PWV) using the Complior SP device and 24-hour pulse wave analysis with the Mobil-O-Graph device.\n* Endothelial Function: Measurement of the endothelial glycocalyx thickness of sublingual capillaries using a Sidestream Dark Field (SDF) camera (GlycoCheck). This is expressed through the perfused boundary region (PBR) index.\n* Cardiac Deformation: Use of two-dimensional strain (speckle tracking) to calculate the Global Longitudinal Strain (GLS) of the LV and LA strain.\n* Oxidative Load: Determination of malondialdehyde (MDA) and protein carbonyls (PCs) levels as markers of oxidative stress using spectrophotometric kits.\n\nStatistical Analysis: Comparisons regarding the changes in these markers over 6 and 12 months will be conducted between the three groups.",[78,79,80],"Lipoprotein Disorder","Arterial Stiffness","Endothelial Dysfunction",[82,83,84,85,86],"lipoprotein a","artrial stiffness","endothelial glycocalyx","myocardial deformation","oxidative stress","2026-03-10",{"date":89,"type":90},"2026-03-11","ACTUAL",{"date":92,"type":90},"2024-09-25",{"date":94,"type":74},"2027-08-17",{"name":5,"class":6},2]